SBIR/STTR Research Award

OmniPlex-Amplified DNA and RNA Samples from Fixed Tissue

Award identifier 97d92c55623b353bcd5e921a992e39663bdc359d2311dc1f098cdd6a8c057b72Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$99,997

Program and phase

SBIR · Phase I

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Rubicon Partners, LLP
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2005-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): A proprietary OmniPlex(tm) technology will be optimized to prepare amplified DNA and RNA samples from formalin-fixed, paraffin-embedded (FFPE) tissues. These OmniPlex products will have predictable performance in downstream applications and allow meaningful genome-wide genetic and gene expression analyses of formalin-fixed tumor specimens for cancer research and diagnostics. These analyses are currently challenging, because no technology can effectively amplify FFPE DNA and RNA samples of variable quality and produce amplified samples with predictable, standardized quality. In the basic OmniPlex process, high quality DNA and RNA samples from fresh tissues and cultured cells are amplified with robust and reproducible efficiencies, but FFPE samples are frequently damaged and/or degraded and amplify with unpredictable and highly variable efficiencies. In Phase I the basic OmniPlex process will be modified in order to produce more robust and reproducible FFPE sample amplification efficiencies, which are required for producing amplified products with predictable, standardized quality. Specific Aim 1 is to identify a real-time quantitative PCR assay that will normalize input FFPE DNA sample amounts better than mass measurements. Specific Aim 2 is to improve the conversion of FFPE samples to amplifiable OmniPlex libraries by modifying reagent and incubation conditions. Finally, Specific Aim 3 is to use in-house quantitative PCR assays to develop quality parameters that predict amplified FFPE sample performance in genetic and gene expression studies. Successful Phase I project results will lead to Phase II studies that test the robustness of the improved process on a large set of normal and tumor samples, uniquely allow DNA and RNA amplification from the same samples, and demonstrate the utility of amplified FFPE samples for cancer research on major commercial genetic and gene expression platforms. The potential commercial applications of this research will be OmniPlex FFPE amplification kits and amplification service projects.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.